Generic placeholder image

Current Nanomedicine

Author(s): Shruthi Puchakayala and Abbaraju Krishna Sailaja*

DOI: 10.2174/2468187312666211217100726

DownloadDownload PDF Flyer Cite As
Formulation and Evaluation of Liposomal Drug Delivery System for Sulfasalazine

Page: [177 - 185] Pages: 9

  • * (Excluding Mailing and Handling)

Abstract

Aim: Aim of the current study is to prepare and characterize sulfasalazine-loaded liposomes to improve the bioavailability of the drug and to lessen the adverse effects of the drug.

Background: Diseases like inflammatory bowel disease can be treated by anti-inflammatory agents like “Sulfasalazine,” It can also be used to treat ulcerative colitis and Crohn’s disease. The biological half-life of sulfasalazine is 5-10 hr; as in the case of conventional therapy, there is a chance of missing the dose. Therefore, frequent administration of drugs is essential to maintain the desired steady-state level. The side effects are thrombocytopenia, megaloblastic anemia, bone marrow depression, folic acid deficiency, impairment of male fertility (Oligospermia), intestinal nephritis due to 5-ASA, diarrhoea, headache, and skin rashes. The bioavailability of sulfasalazine is 15%. This work was undertaken to enhance bioavailability and decrease the side effects.

Objective: The main objective of the study is to improve the solubility of sulfasalazine by formulating a liposomal drug delivery system. The major objective is to develop a liposomal formulation with good stability and the highest entrapment efficiency

Methods: Liposomes were produced by the thin-film hydration method. Nine formulations of liposomes were prepared by varying the concentrations of soya lecithin and cholesterol and changing the drug ratio. The obtained liposomes were characterized for surface morphology, FTIR, particle size, zeta potential, drug content, entrapment efficiency, and in-vitro diffusion studies.

Results: Among the nine formulations of liposomes, F3 was found to be the best formulation with an entrapment efficiency of 97.8% and a zeta potential value of -37.2 mV. Liposomes followed first-order kinetics with a non-fickian diffusion pathway.

Conclusion: Sulfasalazine loaded liposomes were prepared with good stability and the highest entrapment efficiency.

Keywords: Sulfasalazine drug therapy, soya lecithin, therapeutic use, mean vesicle size, zeta potential, drug effects.

Graphical Abstract

[1]
El-Hammadi MM, Arias JL. An update on liposomes in drug delivery: A patent review (2014-2018). Expert Opin Ther Pat 2019; 29(11): 891-907.
[http://dx.doi.org/10.1080/13543776.2019.1679767] [PMID: 31603360]
[2]
Ahmed KS, Hussein SA, Ali AH, Korma SA, Lipeng Q, Jinghua C. Liposome: Composition, characterisation, preparation, and recent innovation in clinical applications. J Drug Target 2019; 27(7): 742-61.
[http://dx.doi.org/10.1080/1061186X.2018.1527337] [PMID: 30239255]
[3]
Anishiyachella daisy ER, Kumar RN, Murugaraj J, Andy R, Mariappan R. Retinal photoreceptors targeting SA-g-AA coated multilamellar liposomes carrier system for cytotoxicity and cellular uptake evaluation. J Liposome Res 2020; 31(2): 203-16.
[http://dx.doi.org/10.1080/08982104.2020.1768111]
[4]
Beltrán-Gracia E, López-Camacho A, Higuera-Ciapara I, et al. Nanomedicine review: Clinical developments in liposomal applications. Cancer Nano 2019; 10: 11.
[http://dx.doi.org/10.1186/s12645-019-0055-y]
[5]
Bhattacharjee A, Das PJ, Adhikari P, et al. Novel drug delivery systems for ocular therapy: With special reference to liposomal ocular delivery. Eur J Ophthalmol 2019; 29(1): 113-26.
[http://dx.doi.org/10.1177/1120672118769776] [PMID: 29756507]
[6]
Sharma D, Ali AAE, Trivedi LR. An updated review on: Liposomes as drug delivery system. PharmaTutor 2018; 6(2): 50-62.
[http://dx.doi.org/10.29161/PT.v6.i2.2018.50]
[7]
Das M, Huang L. Liposomal nanostructures for drug delivery in gastrointestinal cancers. J Pharmacol Exper Ther 2019; 370(3): 647-56.
[http://dx.doi.org/10.1124/jpet.118.254797]
[8]
Has C, Pan S. Vesicle formation mechanisms: An overview. J Liposome Res 2021; 31(1): 90-111.
[http://dx.doi.org/10.1080/08982104.2020.1730401] [PMID: 32066297]
[9]
Khalil RM, Abdelbary A, El Arini SK, Basha M, El-Hashemy HA, Farouk F. Development of tizanidine loaded aspasomes as transdermal delivery system: Ex-vivo and in-vivo evaluation. J Liposome Res 2021; 31(1): 19-29.
[http://dx.doi.org/10.1080/08982104.2019.1684940]
[10]
Kaur M, Singh K, Jain SK. Luliconazole vesicular based gel formulations for its enhanced topical delivery. J Liposome Res 2020; 30(4): 388-406.
[http://dx.doi.org/10.1080/08982104.2019.1682602] [PMID: 31631734]
[11]
Ali I, Saifullah Salim, Ahmed Farid, et al. Synthesis of long-tail nonionic surfactants and their investigation for vesicle formation, drug entrapment, and biocompatibility. J Liposome Res 2020; 30(3): 255-62.
[http://dx.doi.org/10.1080/08982104.2019.1630645] [PMID: 31185766]
[12]
Mithun Maniyar, Avik Chakraborty, Chandrakant Kokare. Formulation and evaluation of letrozole-loaded spray dried liposomes with PEs for topical application. J Liposome Res 2020; 30(3): 274-84.
[http://dx.doi.org/10.1080/08982104.2019.1634723]
[13]
Müller S, Gruhle K, Meister A, Hause G, Drescher S. Bolalipid-doped liposomes: Can bolalipids increase the integrity of liposomes exposed to gastrointestinal fluids? Pharmaceutics 2019; 11(12): 646.
[http://dx.doi.org/10.3390/pharmaceutics11120646] [PMID: 31816937]
[14]
Shukla SK, Kulkarni NS, Chan A, et al. Metformin-encapsulated liposome delivery system: An effective treatment approach against breast cancer. Pharmaceutics 2019; 11(11): 559.
[http://dx.doi.org/10.3390/pharmaceutics11110559] [PMID: 31661947]
[15]
Kumar P, Huo P, Liu B. Formulation strategies for folate-targeted liposomes and their biomedical applications. Pharmaceutics 2019; 11(8): 381.
[http://dx.doi.org/10.3390/pharmaceutics11080381] [PMID: 31382369]
[16]
Amjad M, Raja M. Development and characterization of liposome-enriched ketoprofen liposomal hydrogels. J Pharm Res Int 2019; 27(1): 1-7.
[http://dx.doi.org/10.9734/jpri/2019/v27i130159]
[17]
El-Shenawy AA, Abdelhafez WA, Ismail A, Kassem AA. Formulation and characterization of nanosized ethosomal formulations of antigout model drug (febuxostat) prepared by cold method: In vitro/ex vivo and in vivo assessment. AAPS PharmSciTech 2019; 21(1): 31.
[http://dx.doi.org/10.1208/s12249-019-1556-z] [PMID: 31858305]
[18]
Dave V, Bhardwaj N, Gupta N, Tak K. Herbal ethosomal gel containing luliconazole for productive relevance in the field of biomedicine. 3 Biotech 2020; 10(3): 97.
[http://dx.doi.org/10.1007/s13205-020-2083-z]
[19]
Abdulbaqi IM, Darwis Y, Khan NA, Assi RA, Khan AA. Ethosomalnanocarriers: The impact of constituents and formulation techniques on ethosomal properties, in vivo studies, and clinical trials. Int J Nanomedicine 2016; 11(2279): 2304.
[20]
Madhavi N, Sudhakar B, Reddy KVNS, Ratna JV. Design by optimization and comparative evaluation of vesicular gels of etodolac for transdermal delivery. Drug Dev Ind Pharm 2019; 45(4): 611-28.
[http://dx.doi.org/10.1080/03639045.2019.1569030] [PMID: 30712433]
[21]
Krishnasailaja A, Amareshwar P. Preparation of chitosan coated nanoparticles by emulsion polymerization technique. Asian J Pharm Clin Res 2011; 4(Suppl. 1): 73-4.
[22]
Krishnasailaja A, Shashikala P. An overall review on Liposomal drug delivery systems.2014. Indian J Nov Drug Deliv 2014; 6(2): 112-9.